

NAME OF SPECIALTY SECTION Biotechnology

ANNUAL REPORT: 2011-2012

May 1, 2011 to April 30, 2012

I. Officers/Committees:

<u>Officers</u>	<u>2010-2011</u>	<u>2011-2012</u>
President:	Barbara Mounho	Janet Clarke
Vice President:	Janet Clarke	Hanan Ghantous
Vice President-Elect:	Hanan Ghantous	Laura Andrews
Secretary/Treasurer:	Theresa Reynolds	Theresa Reynolds
Past President	N/A	Barbara Mounho
Councilors:	Leigh Ann Burns Naas Timothy McLachlan Andrea Weir	William Brock Joy Cavagnaro Andrea Weir
PDA Representative:		Fanny Casado-Pena
GSLC Representative:		Jeremy Larson

Committees: Awards, Program

II. Activities:

2012 SOT Annual Meeting Reception was held in San Francisco on March 14.

Approximately 100 people were in attendance.

Dr. Janet Clarke called the meeting to order at 6:00 PM on March 14.

Business Meeting Speaker: Janet Clarke

Meeting Minutes:

- Financial summary to date shared
- Awards presented
- Overview of committee activities
- Featured presentation on the science of winemaking

[Slides presented at the meeting](#)

Awards:

Best Paper: LaRonda L. Morford, Christopher J. Bowman, Diann L. Blanset, Ingrid B. Bøgh, Gary J. Chellman, Wendy G. Halpern, Gerhard F. Weinbauer, and Timothy P. Coogan

Student Achievement: Elaina Chambers and Christopher Kuhlman

Outstanding Young Investigator: Meghan Flaherty

Career Achievement: James Green

2012 SOT Annual Meeting Courses/Sessions:

Continuing Education

- Regulatory sciences: Preclinical Drug development from Small Molecules to Biologics.

Symposia

- Development of Biosimilar Products: Overview of Standards and Regulations.
- Nonclinical Safety Assessment of Dual-Targeting Biotherapeutics.
- Off the Beaten Path: Preclinical Approaches to Safety Evaluation of Cells/Gene Therapy, Vaccines, and Adjuvants.
- Evaluation of Ocular Safety in the Development of New Drugs. (endorsed)

- **Workshops**
- Beyond Traditional Monoclonals New Biologics Formats and Pre-clinical Challenges.
- Challenges and Opportunities in Evaluating Protein Allergenicity Across Biotechnology Industries.
- Therapeutic Immunomodulation and Cancer Risk: Science, Risk Assessment, and Risk Communication. (endorsed)
- T-Dependent Antibody Responses in nonhuman Primates: Challenges and Opportunities. (endorsed)

Endowment Fund Details: Not Applicable.

Newsletters: 3

Teleseminars: None

White Papers: None

Contributions to SOT website: BTSS website.

Other Specialty Section 2011-2012 Activities: Sponsored Session at 2012 AAPS May San Diego, "Nonclinical and Clinical Strategies in the Development of Therapeutic Vaccines."